Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | RARG | P13631 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931933 | 0.89 | PPARG (0.56) | PPARGFFAR1RXRACYP3A4RARG | |
| SCHEMBL1848812 | 0.85 | PPARG (0.60) | PPARGFFAR1RXRACYP3A4RARG | |
| SCHEMBL5810603 | 0.83 | PPARG (0.61) | PPARGFFAR1RXRACYP3A4RARG | |
| SCHEMBL3117517 | 0.82 | PPARG (0.62) | PPARGFFAR1RXRACYP3A4RARG | |
| SCHEMBL2694121 | 0.81 | RAB9A (0.38) | PPARGFFAR1RXRARARGMEN1 | |
| SCHEMBL3240600 | 0.80 | FFAR1 (0.52) | PPARGFFAR1RXRACYP3A4PPARA | |
| SCHEMBL5883336 | 0.80 | PPARG (0.52) | PPARGFFAR1RXRACYP3A4PPARA | |
| SCHEMBL2883389 | 0.79 | PPARG (0.56) | PPARGFFAR1RXRACYP3A4PPARA | |
| SCHEMBL3900454 | 0.79 | FFAR1 (0.62) | PPARGFFAR1RXRACYP3A4PPARA | |
| SCHEMBL6187999 | 0.79 | FFAR1 (0.55) | PPARGFFAR1PPARAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1041977-B1 | USE OF PPAR-GAMMA ACTIVATORS FOR TREATING DERMATOLOGICAL DISORDERS | GALDERMA RES & DEV (FR) | 2008-07-30 | — | — | EP | claimed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102399-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-2788384-B1 | AGONISTIC HUMAN LCAT ANTIGEN BINDING PROTEINS AND THEIR USE IN THERAPY | AMGEN INC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2522721-B1 | Modified lecithin-cholesterol acyltransferase enzymes | AMGEN INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2489730-B1 | Modified lecithin-cholesterol acyltransferase enzymes | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150284471-A1 | Human LCAT Antigen Binding Proteins and Their Use in Therapy | AMGEN INC. | 2015-10-08 | — | — | US | disclosed |
| WO-2004113331-A1 | NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004072022-A1 | COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071504-A1 | COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004046091-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| US-6511670-B1 | Compounds with shorter alkyl chains such as 3,8-dithia-5-docosynoic acid; treating acne and inflammation disorders; peroxisome proliferator activated receptor activators | SOCIETE L'OREAL S.A. (FR) | 2003-01-28 | — | — | US | disclosed |
| US-6403656-B1 | SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C (FR) | 2002-06-11 | — | — | US | disclosed |
| US-20020049249-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PPARG 988/4885FFAR1 224/4885RXRA 2018/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PPARG 621/4885FFAR1 452/4885RXRA 1199/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | PPARG 1/4885FFAR1 10/4885RXRA 4/4885 |
| US-20020049249-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | PPARG 1/4885FFAR1 13/4885RXRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.